1. What It Is (Mechanism of Action)

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHSR-1a). Unlike older GHRPs (GHRP-2, GHRP-6), it stimulates pituitary GH release with minimal stimulation of ACTH, cortisol, or prolactin.

2. Clinical Indications Under Study

Investigated clinically for postoperative bowel recovery (postoperative ileus) following bowel resection.

3. FDA Approval & Regulatory Status

Status:Unapproved for Human Use (FDA 503A Category 2 List)

Unapproved for Human Use (FDA 503A Category 2 List)

4. Human Clinical Evidence Summary

Phase 2 trials for postoperative ileus did not demonstrate sufficient clinical efficacy over standard care, and pharmaceutical development was halted. It lacks completed Phase 3 trials for anti-aging, body composition, or wellness.

5. Known Risks, Side Effects & Boxed Warnings

Transient flushing, headaches, decreased insulin sensitivity, lightheadedness, and elevated IGF-1 risk factors. WADA prohibited substance under Category S2.

7. Why Gray-Market "Research Chemical" Versions Are Risky

Vials purchased through unverified online sources carry high risks of synthetic byproducts, incomplete cleavage sequences, and bacterial contamination.
Peptides Agora Intelligence Wire
Weekly Research Brief

Get Breaking Ipamorelin Clinical Trial Alerts

Receive verified FDA dockets, Phase 3 readouts, and independent HPLC lab audits directly from our medical journalism desk.

HPLC Purity Audits
Independent lab test readouts & endotoxin assays
FDA PCAC Advisory
503A / 503B compounding votes and legal dockets
Phase 2/3 Readouts
Incretin & repair peptide clinical trial data
Zero vendor sponsorship or commercial advertisingUnsubscribe anytime with one click

8. Questions to Ask a Licensed Clinician

If you are discussing this compound with your doctor or healthcare provider, consider bringing these evidence-based questions:

  • Q1: How does selective GHSR-1a agonism differ from physiological pulsatile GH release?
  • Q2: What are the established clinical alternatives for patients with confirmed adult growth hormone deficiency?

9. Primary Peer-Reviewed Sources & Citations

  • [1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed / Source →
  • [2] FDA 503A Bulks Advisory Review: Growth Hormone Secretagogue Peptides. PubMed / Source →